Trial · NCT02325362
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean TCS in mV | day 1 | TCS (Total Chloride Secretion) is the sum of responses in nasal potential difference (NPD) calculated as the mean of the right and left nostril measurements for each patient |
| Primary | Mean TCS in mV | Day 14 | TCS (Total Chloride Secretion) is the sum of responses in nasal potential difference (NPD) calculated as the mean of the right and left nostril measurements for each patient |
| Secondary | TCS difference in mV | day 1 | TCS difference is calculated as the change in measurements of TCS for the right and left nostrils independently for each patient. |
| Secondary | TCS difference in mV | Day 14 | TCS difference is calculated as the change in measurements of TCS for the right and left nostrils independently for each patient. |
| Secondary | Percentage of patients with a TCS response to treatment ≤ - 5 mV | day 1 | The percentage of patients with a TCS response to treatment defined as a difference in TCS from baseline to end-of-treatment ≤ -5mV |
| Secondary | Percentage of patients with a TCS response to treatment ≤ - 5 mV | day 14 | The percentage of patients with a TCS response to treatment defined as a difference in TCS from baseline to end-of-treatment ≤ -5mV |
| Secondary | Percentage of patients with a TCS at end-of-treatment ≤ - 5 mV | day 1 | The percentage of patients with a TCS response at end-of-treatment ≤ -5mV |
| Secondary | Percentage of patients with a TCS at end-of-treatment ≤ - 5 mV | day 14 | The percentage of patients with a TCS response at end-of-treatment ≤ -5mV |
| Secondary | Change of basal NPD in mV | day 1 | Basal NPD at end-of-treatment minus basal NPD at baseline |
| Secondary | Change of basal NPD in mV | day 14 | Basal NPD at end-of-treatment minus basal NPD at baseline |
| Secondary | Change of the response in NPD after superfusion with amiloride | day 1 | NPD after superfusion with amiloride at end-of-treatment minus NPD after superfusion with amiloride at baseline |
| Secondary | Change of the response in NPD after superfusion with amiloride | day 14 | NPD after superfusion with amiloride at end-of-treatment minus NPD after superfusion with amiloride at baseline |
| Secondary | Change of the response in NPD after superfusion with a chloride-free buffer in the presence of amiloride | day 1 | NPD after superfusion with a chloride-free buffer in the presence of amiloride at end-of-treatment minus NPD after superfusion with a chloride-free buffer in the presence of amiloride at baseline |
| Secondary | Change of the response in NPD after superfusion with a chloride-free buffer in the presence of amiloride | day 14 | NPD after superfusion with a chloride-free buffer in the presence of amiloride at end-of-treatment minus NPD after superfusion with a chloride-free buffer in the presence of amiloride at baseline |
| Secondary | Wilschanski's index change | day 1 | Wilschanski's index is defined as (exposant(response to Chloride-free and isoproterenol/response amiloride)): Wilschanski's index at end-of-treatment minus Wilschanski's at baseline |
| Secondary | Wilschanski's index change | day 14 | Wilschanski's index is defined as (exposant(response to Chloride-free and isoproterenol/response amiloride)): Wilschanski's index at end-of-treatment minus Wilschanski's at baseline |
| Secondary | Sweat chloride concentration in mmol/L | day 1 | Sweat chloride concentration at end-of-treatment minus sweat chloride concentration at baseline |
| Secondary | Sweat chloride concentration in mmol/L | day 14 | Sweat chloride concentration at end-of-treatment minus sweat chloride concentration at baseline |
| Secondary | FEV1 (in % of predicted) | day 1 | Pulmonary function FEV1: mean Forced expiry volume in 1 second. FEV1 at end-of-treatment minus FEV1 at baseline |
| Secondary | FEV1 (in % of predicted) | day 14 | Pulmonary function FEV1: mean Forced expiry volume in 1 second. FEV1 at end-of-treatment minus FEV1 at baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02325362/registered